OncoMatch/Clinical Trials/NCT05748145
Metronidazole as Preoperative Therapy in CRC / FusoMetro-001
Is NCT05748145 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Metronidazole Oral for colorectal cancer.
Treatment: Metronidazole Oral — The proposed proof-of concept trial aims at determining the effectiveness of metronidazole in decreasing the Fusobacterium nucleatum load in tissues and possibly on its detrimental effects on tumor cells and tumor microenvironment.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Prior therapy
Cannot have received: anticancer treatment
Any previous anticancer treatment prior resection
Cannot have received: oral or parenteral antibiotic therapy
Oral or parenteral antibiotic therapy within the six weeks prior to enrolment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05748145 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages